Weidauer Stella E, Schmieder Peter, Beerbaum Monika, Schmitz Werner, Oschkinat Hartmut, Mueller Thomas D
Lehrstuhl für Botanik I-Molekulare Pflanzenphysiologie und Biophysik, Julius-von-Sachs Institut für Biowissenschaften (Biozentrum) der Universität Würzburg, Julius-von-Sachs Platz 2, D-97082 Würzburg, Germany.
Biochem Biophys Res Commun. 2009 Feb 27;380(1):160-5. doi: 10.1016/j.bbrc.2009.01.062. Epub 2009 Jan 21.
Sclerostin has been identified as a negative regulator of bone growth. Initially it was considered that Sclerostin performs its regulatory function via acting as a modulator of bone morphogenetic proteins (BMPs) similar to known examples such as Noggin, Chordin, and members of the DAN family. Recent findings, however, show that Sclerostin interferes with the Wnt signaling pathway due to binding to the Wnt co-receptor LRP5 thereby modulating bone growth. As Sclerostin is exclusively produced by osteocytes located in bones, neutralization of its bone-inhibiting functions makes it a highly interesting target for an osteoanabolic therapeutic approach in diseases characterized by bone loss, such as osteoporosis. Despite the huge interest in Sclerostin inhibitors the molecular basis of its function and its interaction with components of the Wnt signaling cascade has remained unclear. Here, we present the NMR structure of murine Sclerostin providing the first insights how Sclerostin might bind to LRP5.
硬化蛋白已被确定为骨生长的负调节因子。最初人们认为,硬化蛋白通过充当骨形态发生蛋白(BMPs)的调节剂来发挥其调节功能,类似于已知的例子,如头蛋白、腱蛋白和DAN家族成员。然而,最近的研究结果表明,硬化蛋白由于与Wnt共受体LRP5结合而干扰Wnt信号通路,从而调节骨生长。由于硬化蛋白仅由位于骨骼中的骨细胞产生,中和其骨抑制功能使其成为治疗以骨质流失为特征的疾病(如骨质疏松症)的骨合成代谢治疗方法的一个极具吸引力的靶点。尽管人们对硬化蛋白抑制剂有着浓厚的兴趣,但其功能的分子基础及其与Wnt信号级联成分的相互作用仍不清楚。在此,我们展示了小鼠硬化蛋白的核磁共振结构,首次揭示了硬化蛋白可能与LRP5结合的方式。